CTNM vs RCL · $429.6M cap vs P/E 26, rev $9.28B
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) versus Royal Caribbean Cruises Ltd (RCL) — a side-by-side from cached financials, not a winner call.
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is a biotechnology company listed on US.
Royal Caribbean Cruises Ltd (RCL) is a travel services company listed on US.
Latest reported CTNM revenue for 2024-09-30 was $0. Net income was -$27.7M. CTNM currently screens at market cap $429.6M.
Latest reported RCL revenue for 2026-06-30 was $9.28B. Net income was $2.07B. RCL currently screens at market cap $85.57B and trailing P/E 25.7.
CTNM currently screens at market cap $429.6M. RCL currently screens at market cap $85.57B and trailing P/E 25.7.
Not investment advice. Open the CTNM and RCL stock pages for the full models.
Not investment advice.